Beyond "Safe and Effective": The urgent need for high-impact smoking cessation medications.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Preventive Medicine

• Publication date

  2021-04-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ypmed.2021.106567PMID 33957153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tobacco Product Use Among Adults — United States, 2019

  2020cited by this paper
• E-cigarettes and smoking cessation in the United States according to frequency of e-cigarette use and quitting duration: analysis of the 2016 and 2017 National Health Interview Surveys.

  2020cited by this paper
• Defining and measuring abstinence in clinical trials of smoking cessation interventions: An updated review.

  2020cited by this paper
• Electronic cigarettes for smoking cessation.

  2020cited by this paper
• Time for The Lancet to realign with the evidence on e-cigarettes?

  2019cited by this paper
• Mobile phone text messaging and app-based interventions for smoking cessation.

  2019cited by this paper
• Association of prevalence of electronic cigarette use with smoking cessation and cigarette consumption in England: a time–series analysis between 2006 and 2017

  2019cited by this paper
• A Randomized Trial of E‐Cigarettes versus Nicotine‐Replacement Therapy

  2019cited by this paper
• Can E-Cigarettes and Pharmaceutical Aids Increase Smoking Cessation and Reduce Cigarette Consumption? Findings From a Nationally Representative Cohort of American Smokers

  2018cited by this paper
• Diminishing benefit of smoking cessation medications during the first year: a meta‐analysis of randomized controlled trials

  2018cited by this paper
• Managing nicotine without smoke to save lives now: Evidence for harm minimization.

  2018cited by this paper
• Quitting Smoking Among Adults - United States, 2000-2015.

  2017cited by this paper
• Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers

  2017cited by this paper
• Complying with the framework convention for tobacco control: an application of the Abridged SimSmoke model to Israel

  2016cited by this paper
• Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

  2016cited by this paper
• Estimating the population impact of e-cigarettes on smoking cessation in England.

  2016cited by this paper
• Smoking and mortality--beyond established causes.

  2015cited by this paper
• Tobacco policy in Israel: 1948–2014 and beyond

  2015cited by this paper
• A call to include people with mental illness and substance use disorders alongside ‘regular’ smokers in smoking cessation research

  2015cited by this paper
• Application of the Abridged SimSmoke model to four Eastern Mediterranean countries

  2015cited by this paper
• Predictors of Smoking Cessation Medication Use among Nonobese and Obese Smokers

  2014cited by this paper
• What is the evidence for hardening in the cigarette smoking population? Trends in nicotine dependence in the U.S., 2002-2012.

  2014cited by this paper
• Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete?

  2014cited by this paper
• Prescription Opioid Abuse: A Literature Review of the Clinical and Economic Burden in the United States

  2014cited by this paper
• A Primer on Effectiveness and Efficacy Trials

  2014cited by this paper
• Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

  2013cited by this paper
• Quitlines and nicotine replacement for smoking cessation: do we need to change policy?

  2012cited by this paper
• Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications.

  2012cited by this paper
• Nicotine receptor partial agonists for smoking cessation

  2012cited by this paper
• Cessation assistance reported by smokers in 15 countries participating in the International Tobacco Control (ITC) policy evaluation surveys.

  2012cited by this paper
• The role of public policies in reducing smoking: the Minnesota SimSmoke tobacco policy model.

  2012cited by this paper
• Australia's experience with varenicline: usage, costs and adverse reactions.

  2011cited by this paper
• Association between use of nicotine replacement therapy for harm reduction and smoking cessation: a prospective study of English smokers

  2011cited by this paper
• The use of cessation assistance among smokers from China: Findings from the ITC China Survey

  2011cited by this paper
• SimSmoke model evaluation of the effect of tobacco control policies in Korea: the unknown success story.

  2010cited by this paper
• The Global Research Neglect of Unassisted Smoking Cessation: Causes and Consequences

  2010cited by this paper
• Treating Tobacco Use and Dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline Executive Summary

  2008cited by this paper
• Over-the-counter nicotine replacement therapy: can its impact on smoking cessation be enhanced?

  2008cited by this paper
• Use of smoking-cessation treatments in the United States.

  2008cited by this paper
• Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness.

  2008cited by this paper
• Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success?

  2006cited by this paper
• Reflections on smoking relapse research.

  2006cited by this paper
• Nicotine replacement therapy for long-term smoking cessation: a meta-analysis

  2006cited by this paper
• The need for dissemination of evidence-based results from research on nicotine and tobacco.

  2003cited by this paper
• Hardening and the hard-core smoker: concepts, evidence, and implications.

  2003cited by this paper
• Tobacco and the global lung cancer epidemic

  2001cited by this paper
• How much does relapse after one year erode effectiveness of smoking cessation treatments? Long term follow up of randomised trial of nicotine nasal spray

  1998cited by this paper
• Integrating individual and public health perspectives for treatment of tobacco dependence under managed health care: A combined stepped-care and matching model

  1996cited by this paper

• Implementing a tobacco-free workplace program at a substance use treatment center: a case study

  2024cites this paper
• Nicotine flux and pharmacokinetics-based considerations for early assessment of nicotine delivery systems

  2024cites this paper
• The influence of sociodemographic, tobacco use, and mental health characteristics on treatment adherence among adults enrolled in a community-based tobacco cessation program

  2024cites this paper
• Quit smoking: methods and outcomes for Norwegian adults

  2023cites this paper
• Perceptions, intentions, and actual use of a consumer nicotine gum

  2023influential citation
• How has the brain disease model of addiction contributed to tobacco control?

  2023cites this paper
• Using varenicline in combination with electronic nicotine delivery systems (ENDS).

  2023cites this paper
• A critique of the Australian National Health and Medical Research Council CEO statement on electronic cigarettes.

  2023cites this paper
• How should nicotine vaping be regulated in Australia?

  2023cites this paper
• Smoking cessation aids and strategies: a population-based survey of former and current smokers in Norway

  2022cites this paper
• Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy

  2022cites this paper
• The 2022 Ferno Award Address: CrEATE, An Efficient Crossover Evaluation of Addiction Treatment Efficacy.

  2022cites this paper